Lactulose Fresenius: Uses, Dosage & Side Effects
An osmotic laxative used for the treatment of chronic constipation and hepatic encephalopathy, available as a convenient oral solution in pre-measured sachets
Lactulose Fresenius is an osmotic laxative containing lactulose as its active ingredient, supplied as a ready-to-use oral solution in pre-measured 10 g sachets. Lactulose is a synthetic disaccharide that is not digested or absorbed in the upper gastrointestinal tract. It passes intact to the colon where it is broken down by bacterial fermentation, lowering the pH and drawing water into the bowel lumen. This dual mechanism makes lactulose effective for two distinct clinical indications: the treatment of chronic constipation and the management of hepatic encephalopathy (a serious neurological complication of liver disease). Lactulose has been used in clinical practice for over five decades and remains one of the most widely prescribed laxatives worldwide, recommended by major international guidelines including the WHO Essential Medicines List.
Quick Facts: Lactulose Fresenius
Key Takeaways
- Lactulose Fresenius is an osmotic laxative that works by drawing water into the colon, softening stools and stimulating bowel movements. It typically takes 24–48 hours to produce a laxative effect.
- It has two main clinical uses: treating chronic constipation in adults and children, and reducing blood ammonia levels in hepatic encephalopathy (a complication of advanced liver disease).
- Unlike stimulant laxatives, lactulose does not cause tolerance or dependency with long-term use, making it suitable for ongoing treatment under medical supervision.
- The most common side effects are gastrointestinal in nature—flatulence, bloating, abdominal cramps, and diarrhea—which are generally mild and often improve with continued use or dose adjustment.
- Lactulose is considered safe during pregnancy and breastfeeding due to minimal systemic absorption, and is listed on the WHO Model List of Essential Medicines for both adults and children.
What Is Lactulose Fresenius and What Is It Used For?
Lactulose Fresenius contains the active substance lactulose, a synthetic sugar (disaccharide) composed of galactose and fructose linked by a beta-1,4 glycosidic bond. This unique chemical structure means that lactulose cannot be broken down by the digestive enzymes of the human small intestine, so it passes through the upper gastrointestinal tract virtually unchanged. When lactulose reaches the colon, it is fermented by the resident bacterial flora—predominantly Lactobacillus and Bifidobacterium species—into low-molecular-weight organic acids, primarily lactic acid, acetic acid, and small amounts of formic acid.
This bacterial fermentation of lactulose produces two therapeutically important effects. First, the resulting organic acids increase the osmotic pressure within the colon, drawing water from the intestinal wall into the bowel lumen. This additional water softens the stool, increases its volume, and stimulates peristalsis (the rhythmic contractions that move contents through the digestive tract). This is the mechanism that makes lactulose an effective laxative for chronic constipation. The onset of action typically occurs within 24 to 48 hours of the first dose, though some patients may require up to 72 hours of regular dosing before achieving a satisfactory bowel movement.
Second, the acidification of the colonic contents by the organic acids lowers the pH of the colonic environment. In this more acidic environment, ammonia (NH3), which freely crosses the intestinal mucosa into the bloodstream, is converted to ammonium ions (NH4+), which are charged molecules that cannot be absorbed through the intestinal wall. This mechanism, known as “ammonia trapping,” reduces the amount of ammonia entering the portal circulation and reaching the brain. Elevated blood ammonia levels (hyperammonaemia) are a key factor in the development of hepatic encephalopathy, a serious neurological condition that can occur in patients with advanced liver disease, particularly cirrhosis. By reducing ammonia absorption, lactulose helps improve mental function, reduce confusion, and prevent episodes of hepatic encephalopathy.
Lactulose has been used in clinical practice since the 1960s and has an extensive safety record spanning more than five decades. It is included on the World Health Organization (WHO) Model List of Essential Medicines, reflecting its importance in global healthcare. The European Medicines Agency (EMA), the U.S. Food and Drug Administration (FDA), and national regulatory authorities worldwide have approved lactulose for the following indications:
- Chronic constipation: Lactulose is indicated for the treatment of habitual constipation in adults and children. It is particularly suitable for patients who require a gentle, non-stimulant laxative for ongoing use, including elderly patients and those with chronic conditions that predispose to constipation. International guidelines, including those from the American College of Gastroenterology (ACG) and the British Society of Gastroenterology (BSG), recommend osmotic laxatives such as lactulose as a first-line or second-line treatment for chronic idiopathic constipation.
- Hepatic encephalopathy: Lactulose is a cornerstone of both the treatment and prevention of hepatic encephalopathy in patients with chronic liver disease. The European Association for the Study of the Liver (EASL) and the American Association for the Study of Liver Diseases (AASLD) both recommend lactulose as first-line treatment for overt hepatic encephalopathy and for secondary prophylaxis to prevent recurrent episodes. Clinical trials have demonstrated that lactulose reduces the risk of recurrent hepatic encephalopathy by approximately 50% compared with placebo.
Lactulose Fresenius is presented as a convenient formulation in pre-measured sachets containing 10 g of lactulose as an oral solution. The sachet format offers practical advantages over bottle presentations: precise dosing without the need for a measuring device, improved portability, and easier use for patients who may have difficulty handling bottles or measuring spoons. The oral solution can be taken undiluted or mixed with water, juice, or other beverages according to patient preference.
In addition to its laxative and ammonia-lowering effects, lactulose has a prebiotic action. By selectively promoting the growth of beneficial Lactobacillus and Bifidobacterium species in the colon, lactulose can help support a healthy gut microbiome. While this prebiotic effect is not a primary therapeutic indication, it may contribute to the overall gastrointestinal benefits of lactulose treatment.
What Should You Know Before Taking Lactulose Fresenius?
Although lactulose is generally considered a very safe medication with minimal systemic absorption, certain medical conditions and circumstances require careful consideration before starting treatment. It is important to provide your healthcare provider with a complete medical history so they can determine whether lactulose is appropriate for you and, if so, what dose and monitoring may be needed.
Contraindications
There are a limited number of situations in which lactulose must not be used. These absolute contraindications include:
- Galactosaemia: Lactulose must not be used in patients with galactosaemia, a rare inherited metabolic disorder in which the body cannot properly metabolize galactose. Since lactulose is broken down into galactose and fructose during its passage through the gastrointestinal tract, even the small amounts of galactose released could be harmful to individuals with this condition. Galactosaemia is typically diagnosed in infancy through newborn screening programmes.
- Gastrointestinal obstruction: Lactulose is contraindicated in patients with confirmed or suspected intestinal obstruction, stricture, or perforation. In these conditions, the increased fluid volume and gas production caused by lactulose could worsen the obstruction or lead to dangerous complications such as bowel rupture. Any patient with sudden severe abdominal pain, complete inability to pass stool or gas, or signs of peritonitis should seek emergency medical attention rather than taking a laxative.
- Hypersensitivity: Patients with a known allergy to lactulose or any of the excipients in the formulation should not take this product. Allergic reactions to lactulose are extremely rare but have been reported.
Warnings and Precautions
Several clinical situations warrant particular caution when using lactulose. Your doctor will weigh the potential benefits against the risks in these circumstances:
- Diabetes mellitus: Lactulose contains small amounts of free sugars, including galactose and lactose, as by-products of its manufacturing process. While the amount is generally negligible at standard constipation doses (typically less than 2 g of galactose and 1 g of lactose per 15 mL), higher doses used for hepatic encephalopathy may provide clinically relevant amounts of absorbable sugar. Patients with diabetes, especially those on insulin therapy, should monitor their blood glucose levels more closely when starting or adjusting lactulose doses. However, most diabetic patients can safely use lactulose at standard constipation doses without significant glycaemic impact.
- Lactose intolerance: Patients with lactose intolerance should be aware that lactulose preparations contain trace amounts of free lactose. At standard laxative doses, the amount of lactose is usually well below the threshold that triggers symptoms in most lactose-intolerant individuals. However, at the higher doses used for hepatic encephalopathy, some patients may experience additional gastrointestinal symptoms related to lactose content.
- Electrolyte imbalance: Prolonged use of lactulose, particularly at high doses or in combination with frequent diarrheal episodes, can lead to significant loss of water and electrolytes, most notably potassium (hypokalaemia). Elderly patients and those with renal impairment are particularly vulnerable. Regular monitoring of serum electrolytes is recommended during long-term lactulose therapy, especially at doses used for hepatic encephalopathy. Symptoms of hypokalaemia include muscle weakness, fatigue, leg cramps, and irregular heartbeat.
- Procedures requiring bowel preparation: Patients undergoing procedures such as colonoscopy that require electrocautery or other electrical procedures should be aware that the hydrogen gas produced by bacterial fermentation of lactulose in the colon is potentially explosive. Adequate bowel cleansing before such procedures is essential to eliminate this risk. Inform your doctor if you are scheduled for any bowel procedures while taking lactulose.
Pregnancy and Breastfeeding
Lactulose is generally considered safe for use during both pregnancy and breastfeeding. Because less than 3% of an oral dose is absorbed from the gastrointestinal tract, systemic exposure to the mother and, consequently, exposure to the fetus or nursing infant is minimal. No teratogenic or embryotoxic effects have been observed in animal reproductive studies, and decades of clinical experience have not revealed any evidence of harm during human pregnancy.
Major international obstetric guidelines, including those from the Royal College of Obstetricians and Gynaecologists (RCOG) and the American College of Obstetricians and Gynecologists (ACOG), include lactulose among the recommended laxatives for managing constipation during pregnancy—a condition that affects up to 40% of pregnant women due to hormonal changes, uterine pressure on the bowel, and iron supplementation. Lactulose does not stimulate uterine contractions and does not cross the placenta in clinically significant amounts.
During breastfeeding, the negligible systemic absorption of lactulose means that clinically significant amounts are not expected to pass into breast milk. Lactulose can therefore be used by breastfeeding mothers who require a laxative, without the need to interrupt breastfeeding. Nevertheless, as with all medications during pregnancy and lactation, it is advisable to use lactulose only when clearly needed and under the guidance of a healthcare provider.
Lactulose is not intended for acute relief of occasional constipation. Its onset of action is 24–48 hours, so it should not be used when rapid bowel evacuation is required. For acute constipation, other faster-acting options such as glycerol suppositories or stimulant laxatives may be more appropriate. Persistent or recurrent constipation lasting more than two weeks should be evaluated by a healthcare provider to rule out underlying causes.
How Does Lactulose Fresenius Interact with Other Drugs?
Because lactulose acts locally in the colon and is absorbed into the systemic circulation to a very limited extent (less than 3%), it has far fewer drug interactions than most orally administered medications. However, there are several clinically relevant interactions that healthcare providers and patients should be aware of. The interactions can be broadly categorized into those that affect the efficacy of lactulose and those where lactulose may alter the effects of other medications.
Major Interactions
The following interactions are considered clinically significant and may require dose adjustments, alternative medications, or enhanced monitoring:
| Interacting Drug | Type of Interaction | Clinical Significance | Recommendation |
|---|---|---|---|
| Neomycin and other non-absorbable antibiotics | Reduced efficacy of lactulose | Neomycin can destroy the colonic bacteria that are essential for the breakdown of lactulose into its active metabolites. This may theoretically reduce both the laxative and ammonia-lowering effects. | Despite this theoretical concern, the combination of lactulose and neomycin is sometimes used deliberately in hepatic encephalopathy as they may have complementary mechanisms. Monitor clinical response carefully. |
| Cardiac glycosides (e.g., digoxin) | Enhanced effect of digoxin | Lactulose-induced hypokalaemia (low potassium) can increase the sensitivity of the heart to digitalis glycosides, raising the risk of potentially dangerous cardiac arrhythmias and digoxin toxicity. | Monitor serum potassium and digoxin levels regularly. Correct any potassium deficiency promptly. Consider potassium supplementation if needed. |
| Diuretics (e.g., furosemide, hydrochlorothiazide) | Additive potassium loss | Both lactulose (at high doses or with diarrhea) and potassium-wasting diuretics can cause hypokalaemia. The combined effect increases the risk of clinically significant electrolyte depletion. | Monitor electrolytes regularly. Consider potassium-sparing diuretics or potassium supplementation as appropriate. |
| Mesalazine (5-ASA) | Altered release of mesalazine | The lowering of colonic pH by lactulose may affect the pH-dependent release mechanisms of certain mesalazine formulations, potentially reducing their efficacy in treating inflammatory bowel disease. | Discuss with your gastroenterologist. Monitoring for adequate disease control is advisable. Alternative laxatives may be considered. |
Minor Interactions
The following interactions are generally of lesser clinical significance but may still warrant awareness:
- Antacids (aluminium- or magnesium-containing): Some antacids may raise the gastric pH and potentially affect the passage of lactulose through the stomach. However, since lactulose is not broken down in the stomach regardless of pH, this interaction is unlikely to be clinically relevant in practice. No dose adjustment is typically required.
- Other laxatives: The concurrent use of multiple laxatives is generally discouraged as it increases the risk of diarrhoea, dehydration, and electrolyte disturbances. If combination laxative therapy is deemed necessary (for example, in severe constipation unresponsive to a single agent), it should be initiated and monitored by a healthcare professional.
- Corticosteroids: Long-term systemic corticosteroid therapy can promote potassium loss. When combined with lactulose, particularly at higher doses, there is a theoretical additive risk of hypokalaemia. Monitoring of serum potassium may be advisable in patients receiving both medications long-term.
- Amphotericin B: Amphotericin B is associated with significant potassium loss. The combination with high-dose lactulose may exacerbate hypokalaemia and should be monitored closely with regular electrolyte checks.
Lactulose may interfere with the results of certain diagnostic tests. The lactulose hydrogen breath test uses lactulose specifically to measure bacterial overgrowth and orocaecal transit time; patients already taking lactulose should inform their gastroenterologist before undergoing this test, as ongoing lactulose use may affect the interpretation of results. Additionally, lactulose may affect blood sugar measurements in diabetic patients, though this is rarely of clinical significance at standard constipation doses.
What Is the Correct Dosage of Lactulose Fresenius?
The dosage of Lactulose Fresenius varies depending on the indication (constipation versus hepatic encephalopathy), the patient's age, and individual response to treatment. Because the therapeutic effect of lactulose depends on reaching the colon and being fermented by colonic bacteria, the dose should be adjusted to achieve the desired clinical outcome: typically one to two soft, formed bowel movements per day for constipation, or two to three soft stools daily for hepatic encephalopathy.
Adults
Constipation — Adults
Starting dose: 15–30 mL (approximately 10–20 g lactulose, equivalent to 1–2 sachets) once daily, preferably taken in the morning.
Maintenance dose: 15–25 mL (10–17 g, or 1–2 sachets) once daily, adjusted according to clinical response.
Duration: The laxative effect usually develops within 24–48 hours. Treatment may be continued for as long as clinically necessary under medical supervision. Once regular bowel habits are established, the dose should be gradually reduced to the minimum effective dose.
Hepatic Encephalopathy — Adults
Acute episodes: 30–50 mL (20–33.5 g, or 2–3 sachets) three times daily, adjusted to produce two to three soft stools per day.
Maintenance/prophylaxis: 25–50 mL (17–33.5 g, or 2–3 sachets) two to three times daily, adjusted to achieve the target stool frequency.
Rectal administration: In severe hepatic encephalopathy where oral administration is not possible (e.g., comatose patients), lactulose may be given as a retention enema: 300 mL of lactulose solution mixed with 700 mL of water, retained for 30–60 minutes and repeated every 4–6 hours as needed.
Children
| Age Group | Starting Dose | Maintenance Dose |
|---|---|---|
| Infants (<1 year) | 5 mL (3.35 g) once daily | 5 mL once daily, adjusted to response |
| Children 1–5 years | 5–10 mL (3.35–6.7 g) once daily | 5–10 mL once daily |
| Children 6–12 years | 10–15 mL (6.7–10 g) once daily | 10–15 mL once daily (1–1.5 sachets) |
| Adolescents 12–18 years | 15 mL (10 g) once daily | 15–30 mL once daily (1–2 sachets) |
Paediatric dosing should always be supervised by a healthcare provider. In infants, lactulose is one of the few laxatives considered safe for use, and its gentle osmotic mechanism makes it suitable even for very young children. The dose should be titrated gradually, starting at the lower end of the recommended range and increasing as needed to achieve one to two soft stools per day.
Elderly
No specific dose adjustment is required for elderly patients. However, elderly individuals are more susceptible to the electrolyte-depleting effects of lactulose, particularly hypokalaemia, and may be more prone to dehydration. Starting at the lower end of the dose range and ensuring adequate fluid intake is recommended. Regular monitoring of serum electrolytes may be advisable during long-term treatment in this population, especially in those taking concurrent medications that affect potassium levels (e.g., diuretics, ACE inhibitors).
Missed Dose
If you forget to take a dose of Lactulose Fresenius, take it as soon as you remember. If it is almost time for your next scheduled dose, skip the missed dose and continue with your regular dosing schedule. Do not take a double dose to make up for a forgotten one. Because lactulose works by gradually softening stool in the colon, missing a single dose is unlikely to cause immediate problems, though regular use is important for maintaining its therapeutic effect.
Overdose
Taking significantly more lactulose than prescribed can lead to excessive diarrhoea, abdominal cramps, and potentially clinically significant fluid and electrolyte losses. Symptoms of overdose may include severe watery diarrhoea, nausea, vomiting, abdominal distension, and dehydration. In severe cases, electrolyte imbalances—particularly hypokalaemia and hypernatraemia—can develop, which may cause muscle weakness, confusion, or cardiac rhythm disturbances.
There is no specific antidote for lactulose overdose. Management is supportive and includes cessation of lactulose administration, oral or intravenous rehydration as appropriate, and correction of any electrolyte abnormalities. Most cases of overdose resolve quickly once the excess lactulose has been evacuated from the bowel. If you suspect an overdose, contact your healthcare provider or local poison control centre immediately.
Tear open the sachet and take the oral solution directly, or mix it with water, juice, or another beverage if preferred. Lactulose can be taken with or without food, though taking it at the same time each day (preferably in the morning with breakfast) helps establish a routine. Ensure adequate fluid intake throughout the day (at least 6–8 glasses of water) to support the osmotic mechanism of lactulose and prevent dehydration.
What Are the Side Effects of Lactulose Fresenius?
Like all medicines, Lactulose Fresenius can cause side effects, although not everybody gets them. Lactulose is generally very well tolerated, and most adverse effects are related to its mechanism of action in the gastrointestinal tract. The bacterial fermentation of lactulose in the colon naturally produces gas (primarily hydrogen, carbon dioxide, and methane), which accounts for the most frequently reported side effect: flatulence. Most gastrointestinal side effects are dose-dependent and can be minimised by starting with a low dose and gradually increasing to the target dose over several days.
It is worth noting that lactulose has been used safely for over fifty years, and serious adverse reactions are extremely uncommon. The following side effects have been observed in clinical trials and post-marketing surveillance. The frequency categories used below follow the international convention established by the Council for International Organizations of Medical Sciences (CIOMS):
Very Common
Affects more than 1 in 10 people
- Flatulence (intestinal gas) — particularly during the first few days of treatment
- Abdominal bloating and distension
Common
Affects 1 in 10 to 1 in 100 people
- Abdominal pain and cramps
- Nausea, particularly at higher doses
- Diarrhoea (usually indicates the dose is too high and should be reduced)
- Vomiting (less common, more frequent in children)
Uncommon
Affects 1 in 100 to 1 in 1,000 people
- Electrolyte imbalance (hypokalaemia, hypernatraemia) — typically with prolonged use at high doses
- Dehydration — usually associated with excessive diarrhoea
Rare
Affects fewer than 1 in 1,000 people
- Allergic reactions (skin rash, itching, urticaria)
- Severe abdominal distension or pain (may warrant investigation)
The gastrointestinal side effects of lactulose, particularly flatulence and bloating, are a direct consequence of its mechanism of action: as colonic bacteria ferment lactulose, they produce gas as a by-product. These effects are most pronounced during the first few days of treatment as the colonic microbiome adapts to the new substrate. Most patients find that flatulence diminishes significantly after the first week of continuous use. Starting with a low dose and gradually titrating upward can help minimise these initial symptoms.
Diarrhoea during lactulose therapy is usually a sign that the dose is too high rather than a true adverse reaction. In clinical practice, diarrhoea is managed by reducing the dose until the desired stool consistency is achieved—typically one to two soft, formed stools per day. If diarrhoea persists despite dose reduction, the patient should be evaluated for other potential causes.
Electrolyte disturbances, particularly hypokalaemia (low potassium), are primarily a concern with the higher doses used for hepatic encephalopathy or when lactulose causes persistent diarrhoea. Regular monitoring of serum electrolytes is recommended for patients on long-term, high-dose therapy. Signs and symptoms of hypokalaemia include muscle weakness, fatigue, leg cramps, constipation (paradoxically), and cardiac arrhythmias. Prompt correction of potassium depletion is important, particularly in patients who are also taking digoxin or other medications that are sensitive to potassium levels.
Seek immediate medical help if you experience signs of a severe allergic reaction (difficulty breathing, swelling of the face, lips, tongue, or throat, severe skin rash), severe abdominal pain that does not resolve, bloody or black tarry stools, or signs of severe dehydration (extreme thirst, very dry mouth, rapid heartbeat, dizziness, or fainting). While these reactions are extremely rare with lactulose, they require prompt medical evaluation.
How Should You Store Lactulose Fresenius?
Proper storage of lactulose is important to maintain the quality and efficacy of the medication throughout its shelf life. Lactulose is a sugar-based solution that is chemically stable under normal conditions, but extreme temperatures or improper storage can affect its properties.
Store the sachets at room temperature, ideally below 25°C (77°F). Avoid storing lactulose in areas subject to high temperatures, such as near radiators, in direct sunlight, or in a car during summer months. High temperatures can accelerate the degradation of lactulose and may cause the formation of hydroxymethylfurfural (HMF) and other degradation products. While HMF is not toxic at the low levels that may form, it can reduce the potency of the medication over time.
Do not freeze lactulose solution. Freezing can alter the physical properties of the solution, potentially affecting its consistency and the uniformity of the active ingredient distribution. If a sachet has been accidentally frozen and then thawed, it should not be used.
Keep the sachets in their original packaging until ready to use. This protects them from light and moisture. Once a sachet is opened, the contents should be taken immediately; any remaining solution should be discarded. Unlike bottle formulations that may be used over several weeks after opening, the single-use sachet format eliminates concerns about contamination or stability after opening.
As with all medications, keep Lactulose Fresenius out of the reach and sight of children. Do not use the medication after the expiry date stated on the sachet and the outer carton (after “EXP”). The expiry date refers to the last day of the stated month. Do not dispose of medications in household waste or via the sewage system. Return unused or expired sachets to your pharmacy for proper disposal in accordance with local environmental regulations.
What Does Lactulose Fresenius Contain?
Understanding the composition of Lactulose Fresenius is important for patients with specific dietary restrictions, allergies, or metabolic conditions. The formulation is relatively simple, reflecting the fact that lactulose is a chemically well-defined synthetic disaccharide:
- Active ingredient: Lactulose 10 g per sachet. Lactulose (4-O-beta-D-galactopyranosyl-D-fructose) is a synthetic disaccharide that does not occur naturally. It is manufactured by isomerisation of lactose under alkaline conditions, a process that converts the glucose moiety of lactose into fructose while retaining the galactose component.
- Other sugars (residual): The manufacturing process inevitably produces small amounts of related sugars, including free galactose (typically ≤2.2 g per 15 mL), free lactose (typically ≤1.2 g per 15 mL), and trace amounts of epilactose and other disaccharide isomers. These residual sugars are of particular relevance for patients with galactosaemia (absolute contraindication), diabetes mellitus (may affect blood glucose), and lactose intolerance (potential gastrointestinal symptoms at higher doses).
- Purified water: Used as the vehicle for the oral solution to ensure palatability and ease of administration.
Lactulose Fresenius does not contain preservatives, artificial colours, or flavourings in the sachet formulation. The solution is clear to slightly yellow and has a sweet taste. Slight variations in colour between batches are normal and do not affect the quality or efficacy of the product.
The sachet format provides precise, pre-measured dosing: each sachet contains exactly 10 g of lactulose, eliminating the need for measuring devices and reducing the risk of dosing errors. This is particularly advantageous for elderly patients or those with dexterity issues who may find it difficult to use measuring cups or syringes with bottle formulations.
Lactulose has a molecular formula of C12H22O11 and a molecular weight of 342.30 g/mol. It is freely soluble in water and has a sweet taste approximately 40–60% as sweet as sucrose. The pharmacological activity of lactulose depends entirely on its reaching the colon intact, where it serves as a substrate for bacterial fermentation. This requires that it is not broken down by the acidic conditions of the stomach or the enzymes of the small intestine—a property ensured by its beta-glycosidic bond, which human digestive enzymes cannot cleave.
Frequently Asked Questions About Lactulose Fresenius
Lactulose Fresenius is an osmotic laxative used primarily for two conditions: chronic constipation and hepatic encephalopathy. For constipation, it works by drawing water into the bowel to soften stools and stimulate bowel movements, typically producing results within 24–48 hours. For hepatic encephalopathy (a neurological complication of advanced liver disease), it reduces blood ammonia levels by acidifying the colonic contents, converting absorbable ammonia into non-absorbable ammonium ions. It is listed on the WHO Essential Medicines List and has been used safely for over 50 years.
The laxative effect of lactulose typically begins within 24 to 48 hours after the first dose. Some patients may notice effects sooner, while others may need up to 72 hours of regular use. Unlike stimulant laxatives that work within hours, lactulose works gradually by drawing water into the colon through osmosis. It is important to take lactulose consistently as directed rather than expecting immediate results. For hepatic encephalopathy, the ammonia-lowering effect also develops within 24 to 48 hours of starting treatment.
Yes, lactulose can be taken daily for extended periods under medical supervision. Unlike stimulant laxatives (such as senna or bisacodyl), lactulose does not cause tolerance, meaning it remains effective over time without requiring dose increases. It also does not cause dependency or damage the colonic nerve plexus. However, long-term use should be monitored by a healthcare provider, particularly to check for electrolyte imbalances (especially potassium). Adequate fluid intake is important during prolonged lactulose therapy.
Lactulose is generally considered safe during pregnancy. Because less than 3% of the oral dose is absorbed into the bloodstream, systemic exposure to the mother and fetus is minimal. No harmful effects have been observed in animal studies or decades of clinical use in pregnant women. Major obstetric guidelines recommend lactulose as one of the preferred laxatives for managing constipation during pregnancy. It does not stimulate uterine contractions. Nonetheless, pregnant women should consult their healthcare provider before starting any medication.
The most common side effects of lactulose are gastrointestinal and are related to its mechanism of action: flatulence (gas), abdominal bloating, and distension are very common, particularly during the first few days of treatment. Abdominal cramps, nausea, and diarrhoea are common but usually respond to dose adjustment. These side effects typically diminish after the first week as the gut microbiome adapts. Starting with a low dose and gradually increasing can help minimise these initial symptoms. Serious side effects are extremely rare.
Both lactulose and polyethylene glycol (PEG, also known as macrogol) are osmotic laxatives, but they differ in several ways. PEG is not fermented by colonic bacteria, so it produces less gas and bloating than lactulose. Some clinical trials suggest PEG may be slightly more effective for chronic constipation with fewer gastrointestinal side effects. However, lactulose has the unique advantage of also being effective for hepatic encephalopathy through its ammonia-lowering mechanism—a property PEG does not have. Lactulose also has a prebiotic effect that supports beneficial gut bacteria. The choice between them depends on the clinical situation and patient preference.
References
- European Medicines Agency (EMA). Lactulose – Summary of Product Characteristics. Available from: ema.europa.eu. Accessed January 2026.
- World Health Organization (WHO). WHO Model List of Essential Medicines – 23rd List. Geneva: WHO; 2023.
- Vilstrup H, Amodio P, Bajaj J, et al. Hepatic encephalopathy in chronic liver disease: 2014 Practice Guideline by the American Association for the Study of Liver Diseases and the European Association for the Study of the Liver. Hepatology. 2014;60(2):715–735.
- Sharma BC, Sharma P, Agrawal A, Sarin SK. Secondary prophylaxis of hepatic encephalopathy: an open-label randomized controlled trial of lactulose versus placebo. Gastroenterology. 2009;137(3):885–891.
- Lee-Robichaud H, Thomas K, Morgan J, Nelson RL. Lactulose versus polyethylene glycol for chronic constipation. Cochrane Database Syst Rev. 2010;(7):CD007570.
- American College of Gastroenterology (ACG). Wald A, et al. ACG Clinical Guideline: Management of Benign Anorectal Disorders. Am J Gastroenterol. 2021;116(10):1987–2008.
- British National Formulary (BNF). Lactulose monograph. National Institute for Health and Care Excellence (NICE). Updated 2025.
- European Association for the Study of the Liver (EASL). EASL Clinical Practice Guidelines on the management of hepatic encephalopathy. J Hepatol. 2022;77(3):807–824.
- Bharucha AE, Pemberton JH, Locke GR. American Gastroenterological Association technical review on constipation. Gastroenterology. 2013;144(1):218–238.
- Gluud LL, Vilstrup H, Morgan MY. Non-absorbable disaccharides versus placebo/no intervention and lactulose versus lactitol for the prevention and treatment of hepatic encephalopathy in people with cirrhosis. Cochrane Database Syst Rev. 2016;(5):CD003044.
Editorial Team
Medical Content
Written by licensed physicians specializing in gastroenterology and clinical pharmacology
Medical Review
Reviewed by the iMedic Medical Review Board according to WHO, EMA, FDA, and BNF guidelines
Evidence Standard
Level 1A evidence based on systematic reviews, meta-analyses, and randomized controlled trials
Editorial Independence
No pharmaceutical company funding, sponsorship, or advertising influences our content
Last medical review: | Next scheduled review: